What Is the Biological and Clinical Relevance of Fibrin?

As our knowledge of the structure and functions of fibrinogen and fibrin has increased tremendously, several key findings have given some people a superficial impression that the biological and clinical significance of these clotting proteins may be less than earlier thought. Most strikingly, studies of fibrinogen knockout mice demonstrated that many of these mice survive to weaning and beyond, suggesting that fibrin(ogen) may not be entirely necessary. Humans with afibrinogenemia also survive. Furthermore, in recent years, the major emphasis in the treatment of arterial thrombosis has been on inhibition of platelets, rather than fibrin. In contrast to the initially apparent conclusions from these results, it has become increasingly clear that fibrin is essential for hemostasis; is a key factor in thrombosis; and plays an important biological role in infection, inflammation, immunology, and wound healing. In addition, fibrinogen replacement therapy has become a preferred, major treatment for severe bleeding in trauma and surgery. Finally, fibrin is a unique biomaterial and is used as a sealant or glue, a matrix for cells, a scaffold for tissue engineering, and a carrier and/or a vector for targeted drug delivery.

[1]  D. Witte,et al.  Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin αMβ2 binding motif , 2007 .

[2]  D. Witte,et al.  Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. , 2007, The Journal of clinical investigation.

[3]  Max Potters,et al.  Structural hierarchy governs fibrin gel mechanics. , 2010, Biophysical journal.

[4]  J. Frampton,et al.  Thrombin‐induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb , 2003, British journal of pharmacology.

[5]  N. Killeen,et al.  Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signalling and platelet function , 1999, Nature.

[6]  J. Melero-Martin,et al.  Type I collagen, fibrin and PuraMatrix matrices provide permissive environments for human endothelial and mesenchymal progenitor cells to form neovascular networks , 2011, Journal of Tissue Engineering and Regenerative Medicine.

[7]  W. Schobersberger,et al.  Time for changing coagulation management in trauma-related massive bleeding , 2009, Current opinion in anaesthesiology.

[8]  J. Forrester Malpighi's De polypo cordis: an annotated translation. , 1995, Medical history.

[9]  S. E. James,et al.  A review of tissue-engineered skin bioconstructs available for skin reconstruction , 2010, Journal of The Royal Society Interface.

[10]  P. Janmey,et al.  Fibrin gels and their clinical and bioengineering applications , 2009, Journal of The Royal Society Interface.

[11]  G. Kovacs,et al.  Evaluation of D-Dimer in the diagnosis of suspected deep-vein thrombosis , 2004 .

[12]  Y. Sakata,et al.  A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[13]  M. Carr Development of platelet contractile force as a research and clinical measure of platelet function , 2007, Cell Biochemistry and Biophysics.

[14]  T. Haas,et al.  The effect of fibrinogen concentrate on thrombocytopenia , 2007, Journal of thrombosis and haemostasis : JTH.

[15]  W. Tracz,et al.  Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. , 2009, Blood.

[16]  Chengyu Liu,et al.  Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. , 2012, Blood.

[17]  J. Bennett,et al.  Platelet‐Fibrinogen Interactions , 2001, Annals of the New York Academy of Sciences.

[18]  John J. Foxe,et al.  Towards obtaining spatiotemporally precise responses to continuous sensory stimuli in humans: A general linear modeling approach to EEG , 2014, NeuroImage.

[19]  S. Hsiao,et al.  Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. , 2008, Blood.

[20]  K. Gutkowski,et al.  Coagulopathy in liver diseases. , 2010, Advances in medical sciences.

[21]  A. Undas How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice? , 2016, Seminars in Thrombosis & Hemostasis.

[22]  M. Flick,et al.  Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in Staphylococcus aureus Infection , 2016, Seminars in Thrombosis & Hemostasis.

[23]  Dennis E. Discher,et al.  Multiscale Mechanics of Fibrin Polymer: Gel Stretching with Protein Unfolding and Loss of Water , 2009, Science.

[24]  R. Lassila Clinical Use of Factor XIII Concentrates , 2016, Seminars in Thrombosis & Hemostasis.

[25]  J. Weisel,et al.  Composition of coronary thrombus in acute myocardial infarction. , 2011, Journal of the American College of Cardiology.

[26]  T. Lisman,et al.  Alterations in Fibrin Structure in Patients with Liver Diseases , 2016, Seminars in Thrombosis & Hemostasis.

[27]  S. Diamond,et al.  Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. , 2013, Blood.

[28]  S. Coughlin,et al.  Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. , 2015, Blood.

[29]  W. Lam,et al.  Factor XIII activity mediates red blood cell retention in venous thrombi. , 2014, Journal of Clinical Investigation.

[30]  C. T. Ammollo,et al.  Sepsis, thrombosis and organ dysfunction. , 2012, Thrombosis research.

[31]  C. Samama Fibrinogen Concentrates for Acquired Fibrinogen Deficiencies? , 2016, Seminars in Thrombosis & Hemostasis.

[32]  N. Killeen,et al.  Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. , 1999, Nature.

[33]  S. Diamond,et al.  Blood Clots Are Rapidly Assembled Hemodynamic Sensors: Flow Arrest Triggers Intraluminal Thrombus Contraction , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[34]  M. Mosesson Update on antithrombin I (fibrin) , 2007, Thrombosis and Haemostasis.

[35]  S. Kuroda,et al.  Fibrin matrix provides a suitable scaffold for bone marrow stromal cells transplanted into injured spinal cord: A novel material for CNS tissue engineering , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[36]  P. Grant,et al.  Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. , 2008, Journal of vascular surgery.

[37]  J. Weisel,et al.  Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[38]  T. Nakabayashi,et al.  Plasma soluble fibrin monomer complex as a marker of coronary thrombotic events in patients with acute myocardial infarction. , 2009, The Tohoku journal of experimental medicine.

[39]  J. Zalewski,et al.  Polyhedrocytes in intracoronary thrombi from patients with ST-elevation myocardial infarction. , 2015, International journal of cardiology.

[40]  J. Degen,et al.  Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. , 1995, Genes & development.

[41]  Marco M. Domingues,et al.  The (Patho)physiology of Fibrinogen γ′ , 2016, Seminars in Thrombosis & Hemostasis.

[42]  D. Fries,et al.  Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs , 2014, Transfusion.

[43]  M. Hanss,et al.  A Database for Human Fibrinogen Variants , 2001, Annals of the New York Academy of Sciences.

[44]  A. Ichinose,et al.  Impaired clot retraction in factor XIII A subunit-deficient mice. , 2010, Blood.

[45]  A. Casini,et al.  Clinical Features and Management of Congenital Fibrinogen Deficiencies , 2016, Seminars in Thrombosis & Hemostasis.

[46]  M. Freund,et al.  Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. , 2009, Blood.

[47]  M Galarza,et al.  Role of EVICEL Fibrin Sealant to Assist Hemostasis in Cranial and Spinal Epidural Space: A Neurosurgical Clinical Study. , 2015, Surgical technology international.

[48]  Rustem I. Litvinov,et al.  Mechanisms of fibrin polymerization and clinical implications. , 2013, Blood.

[49]  I. Ay,et al.  Fibrin-targeted PET probes for the detection of thrombi. , 2013, Molecular pharmaceutics.

[50]  R. Porte,et al.  Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. , 2010, Blood.

[51]  H. Bianco-Peled,et al.  The effect of structural alterations of PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular migration. , 2006, Biomaterials.

[52]  A. Casini,et al.  Congenital Fibrinogen Disorders: An Update , 2013, Seminars in Thrombosis & Hemostasis.

[53]  J. Weisel,et al.  A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots , 2002, Circulation research.

[54]  D. Fries,et al.  Role of fibrinogen in trauma-induced coagulopathy. , 2010, British journal of anaesthesia.

[55]  A. Casini,et al.  Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management , 2015, Journal of thrombosis and haemostasis : JTH.

[56]  A. Lebreton,et al.  Natural history of patients with congenital dysfibrinogenemia. , 2015, Blood.

[57]  I. Donati,et al.  Adhesive and sealant interfaces for general surgery applications. , 2016, Journal of biomedical materials research. Part B, Applied biomaterials.

[58]  S. Brennan,et al.  Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain , 2007, Haematologica.

[59]  Peter Caravan,et al.  Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. , 2008, Angewandte Chemie.

[60]  P. de Moerloose,et al.  Congenital Fibrinogen Disorders , 2009, Seminars in thrombosis and hemostasis.

[61]  R. Tiedt,et al.  Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. , 2007, Blood.

[62]  C. Camargo,et al.  Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. , 2010, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[63]  E. Stępień,et al.  Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke , 2009, Stroke.

[64]  N. Salamon,et al.  CT and MRI Early Vessel Signs Reflect Clot Composition in Acute Stroke , 2011, Stroke.

[65]  D. Fries The early use of fibrinogen, prothrombin complex concentrate, and recombinant‐activated factor VIIa in massive bleeding , 2013, Transfusion.

[66]  M. Liberatore,et al.  Elastic behavior and platelet retraction in low- and high-density fibrin gels. , 2015, Biophysical journal.

[67]  J. Hartwig,et al.  Cell mechanics: Contracting to stiffness. , 2011, Nature materials.

[68]  Peter Caravan,et al.  Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. , 2012, Bioconjugate chemistry.

[69]  A. Stammers,et al.  Soluble fibrin monomer complex and cardiopulmonary bypass. , 2009, The journal of extra-corporeal technology.

[70]  P. Innerhofer,et al.  The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. , 2013, Injury.

[71]  Rennian Wang,et al.  Fibrin, a scaffold material for islet transplantation and pancreatic endocrine tissue engineering. , 2015, Tissue engineering. Part B, Reviews.

[72]  S. Diamond,et al.  A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. , 2014, Blood.

[73]  S. Kojima,et al.  Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts. , 2013, Blood.

[74]  J. Martinez,et al.  Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. , 1978, The Journal of clinical investigation.

[75]  J. Luyendyk,et al.  Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association? , 2016, Seminars in Thrombosis & Hemostasis.

[76]  Richard T. Lee,et al.  Custom Design of the Cardiac Microenvironment With Biomaterials , 2005, Circulation research.

[77]  J. Weisel,et al.  Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. , 2002, Blood.

[78]  G. Koenderink,et al.  Factor XIII stiffens fibrin clots by causing fiber compaction , 2014, Journal of thrombosis and haemostasis : JTH.

[79]  T. van der Poll,et al.  A Short Contemporary History of Disseminated Intravascular Coagulation , 2014, Seminars in Thrombosis & Hemostasis.

[80]  C. Doillon,et al.  Angiogenic response of endothelial cells seeded dispersed versus on beads in fibrin gels , 2007, Angiogenesis.

[81]  D. Witte,et al.  Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo , 2004 .

[82]  P. Grant,et al.  Altered Fibrin Clot Structure in the Healthy Relatives of Patients With Premature Coronary Artery Disease , 2002, Circulation.

[83]  J. Weisel,et al.  The Platelet Integrin αIIbβ3 Differentially Interacts with Fibrin Versus Fibrinogen* , 2016, The Journal of Biological Chemistry.

[84]  W. Lam,et al.  Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. , 2015, Blood.

[85]  A. Casini,et al.  Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders , 2016, Seminars in Thrombosis & Hemostasis.

[86]  L. Armengou,et al.  Fibrin deposits and organ failure in newborn foals with severe septicemia. , 2008, Journal of veterinary internal medicine.

[87]  V. Schroeder,et al.  Factor XIII: Structure and Function , 2016, Seminars in Thrombosis & Hemostasis.

[88]  L Sedel,et al.  A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. , 2003, Biomaterials.

[89]  M. Fatima,et al.  Fibrin matrices: The versatile therapeutic delivery systems. , 2015, International journal of biological macromolecules.

[90]  Peter Caravan,et al.  EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. , 2008, Journal of the American Chemical Society.

[91]  J. Davidson,et al.  Wound-healing defects in mice lacking fibrinogen. , 2001, Blood.

[92]  E. Stępień,et al.  Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome , 2008, Diabetes Care.

[93]  A. Słowik,et al.  Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. , 2010, Thrombosis research.

[94]  S. Bates D-Dimer Assays in Diagnosis and Management of Thrombotic and Bleeding Disorders , 2012, Seminars in Thrombosis & Hemostasis.

[95]  H. Saito,et al.  Advances in the understanding of MYH9 disorders , 2010, Current opinion in hematology.

[96]  T. Haas,et al.  The In Vitro Effects of Fibrinogen Concentrate, Factor XIII and Fresh Frozen Plasma on Impaired Clot Formation After 60% Dilution , 2008, Anesthesia and analgesia.

[97]  K. Tomita,et al.  Changes of the soluble fibrin monomer complex level during the perioperative period of hip replacement surgery , 2008, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[98]  Mortimer Poncz,et al.  T2 magnetic resonance: a diagnostic platform for studying integrated hemostasis in whole blood--proof of concept. , 2014, Clinical chemistry.

[99]  L. Brass,et al.  Shaping the platelet response to vascular injury , 2014, Current opinion in hematology.

[100]  É. Katona,et al.  Diagnosis and Management of Congenital and Acquired FXIII Deficiencies , 2016, Seminars in Thrombosis & Hemostasis.

[101]  P. Cabrales,et al.  Effects of Fibrinogen Concentrate After Shock/Resuscitation: A Comparison Between In Vivo Microvascular Clot Formation and Thromboelastometry* , 2013, Critical care medicine.

[102]  D. Witte,et al.  Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. , 2004, The Journal of clinical investigation.

[103]  Tai-De Li,et al.  Mechanics and contraction dynamics of single platelets and implications for clot stiffening. , 2011, Nature materials.

[104]  A. Wolberg,et al.  Newly-Recognized Roles of Factor XIII in Thrombosis , 2016, Seminars in Thrombosis & Hemostasis.

[105]  F. Peyvandi,et al.  Fibrinogen replacement therapy for congenital fibrinogen deficiency , 2011, Journal of thrombosis and haemostasis : JTH.

[106]  L. Rauova,et al.  Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. , 2014, Blood.

[107]  J. Weisel,et al.  Structural basis for the nonlinear mechanics of fibrin networks under compression. , 2014, Biomaterials.